World Glaucoma Congress data show impact of new Nicox med

3 July 2023

Additional data on NCX 470 have been presented at the World Glaucoma Congress (WGC) by developer Nicox (Euronext: COX), a French ophthalmology company.

The company is presenting data from the Phase III MONT BLANC trial of the novel NO-donating bimatoprost eye drop, currently under development for the lowering of IOP in people with open-angle glaucoma or ocular hypertension.

Nicox has already announced positive top-line results from the study, showing the primary objective of non-inferiority was met, compared to standard of care.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK